Suchergebnisse - "O3J8G9O825"

PubPharm (119)

1

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

2

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance

enthalten in: The Journal of antimicrobial chemotherapy | 2024

von Abdullahi, A. | Diaz, A. | Fopoussi, O. | +5

3

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children : A Substudy of the CHAPAS-4 Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waalewijn, H. | Szubert, A. | Wasmann, R. | +18

4

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older : a PK substudy of the SMILE trial

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Abdalla, S. | Compagnucci, A. | Zheng, Y. | +39

5

Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir : a DUALIS sub-study

enthalten in: AIDS care | 2022

von Olliges, E. | Bührlen, B. | Fischer, F. | +14

6

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) : week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2022

von Paton, N. | Musaazi, J. | Kityo, C. | +101

CommentIn: Lancet HIV. 2022 Jun;9(6):e368-e369. - PMID 35460602

7

Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

enthalten in: HIV research & clinical practice | 2021

von Monin, M. | Kümmerle, T. | Schneider, J. | +16

8

Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial : NEAT 001/ANRS 143 LONG TERM study

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Raffi, F. | Gaultier, A. | Pozniak, A. | +8

9

Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Ebrahim, I. | Maartens, G. | Wiesner, L. | +3

10

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Dickinson, L. | Gurjar, R. | Stöhr, W. | +113

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]